SG11201900546UA - Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof - Google Patents
Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereofInfo
- Publication number
- SG11201900546UA SG11201900546UA SG11201900546UA SG11201900546UA SG11201900546UA SG 11201900546U A SG11201900546U A SG 11201900546UA SG 11201900546U A SG11201900546U A SG 11201900546UA SG 11201900546U A SG11201900546U A SG 11201900546UA SG 11201900546U A SG11201900546U A SG 11201900546UA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- spiro
- lactam
- pct
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/20—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662369534P | 2016-08-01 | 2016-08-01 | |
| PCT/US2017/044861 WO2018026792A1 (en) | 2016-08-01 | 2017-08-01 | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201900546UA true SG11201900546UA (en) | 2019-02-27 |
Family
ID=59593195
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201900546UA SG11201900546UA (en) | 2016-08-01 | 2017-08-01 | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US11028095B2 (ko) |
| EP (1) | EP3490994B8 (ko) |
| JP (1) | JP2019527235A (ko) |
| KR (1) | KR102462288B1 (ko) |
| CN (1) | CN109661398B (ko) |
| AU (1) | AU2017306158B2 (ko) |
| BR (1) | BR112019001926A2 (ko) |
| CA (1) | CA3031562A1 (ko) |
| CL (1) | CL2019000249A1 (ko) |
| CO (1) | CO2019000944A2 (ko) |
| EA (1) | EA201990425A1 (ko) |
| ES (1) | ES2979128T3 (ko) |
| IL (1) | IL264496B (ko) |
| MX (1) | MX2019001322A (ko) |
| PE (1) | PE20190502A1 (ko) |
| SG (1) | SG11201900546UA (ko) |
| WO (1) | WO2018026792A1 (ko) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5702288B2 (ja) | 2008-09-18 | 2015-04-15 | ノースウエスタン ユニバーシティ | Ｎｍｄａレセプターモジュレータ及びその用途 |
| US9512134B2 (en) | 2013-01-29 | 2016-12-06 | Aptinyx, Inc. | Spiro-lactam NMDA receptor modulators and uses thereof |
| AU2017306152A1 (en) | 2016-08-01 | 2019-01-31 | Aptinyx Inc. | Spiro-lactam NMDA receptor modulators and uses thereof |
| CN109843889B (zh) | 2016-08-01 | 2022-03-15 | 阿普廷伊克斯股份有限公司 | 螺-内酰胺nmda调节剂和使用其的方法 |
| KR102465757B1 (ko) | 2016-08-01 | 2022-11-09 | 앱티닉스 인크. | 스피로-락탐 nmda 수용체 조정제 및 그의 용도 |
| CN109661398B (zh) | 2016-08-01 | 2022-07-05 | 阿普廷伊克斯股份有限公司 | 螺-内酰胺和二-螺-内酰胺nmda受体调节剂及其用途 |
| EP3490974B1 (en) | 2016-08-01 | 2023-12-06 | Tenacia Biotechnology (Hong Kong) Co., Limited | Spiro-lactam nmda receptor modulators and uses thereof |
| US10416340B2 (en) | 2017-05-27 | 2019-09-17 | ADANI Systems, Inc. | Autonomous container-transportable system for vehicle scanning |
| BR112020015710A2 (pt) | 2018-01-31 | 2020-12-08 | Aptinyx Inc. | Moduladores de espiro-lactamas de receptores nmda e usos dos mesmos |
| WO2019152681A1 (en) * | 2018-01-31 | 2019-08-08 | Aptinyx Inc. | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof |
| US12012413B2 (en) | 2019-11-11 | 2024-06-18 | Tenacia Biotechnology (Hong Kong) Co., Limited | Methods of treating painful diabetic peripheral neuropathy |
Family Cites Families (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0180398A1 (en) | 1984-10-26 | 1986-05-07 | The Regents Of The University Of California | Synthesis of beta-lactam |
| CA1305177C (en) | 1987-06-30 | 1992-07-14 | Yasufumi Ohfune | Carboxycyclopropylglycine and process for producing the same |
| US4904681A (en) | 1987-12-01 | 1990-02-27 | G. D. Searle & Co. | D-cycloserine and its prodrugs as cognitive enhancers |
| EP0360390A1 (en) | 1988-07-25 | 1990-03-28 | Glaxo Group Limited | Spirolactam derivatives |
| US5061721A (en) | 1989-03-15 | 1991-10-29 | G. D. Searle & Co. | Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder |
| US5086072A (en) | 1990-06-18 | 1992-02-04 | The United States Of America As Represented By The Department Of Health And Human Services | Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex |
| CA2058975C (en) | 1990-10-30 | 2000-06-06 | Shuichi Kasai | Antiinflammatory gel preparation |
| US5168103A (en) | 1991-01-22 | 1992-12-01 | American Home Products Corporation | [[2-(amino-3,4-dioxo-1-cyclobuten-1-yl) amino]alkyl]-acid derivatives |
| FR2692268B1 (fr) | 1992-06-15 | 1994-08-19 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides ayant une activité de récepteur NMDA, acides nucléiques codant pour ces polypeptides et utilisations. |
| SE9301667D0 (sv) | 1993-05-14 | 1993-05-14 | Kabi Pharmacia Ab | New use |
| US5523323A (en) | 1993-09-14 | 1996-06-04 | Maccecchini; Maria-Luisa | Use of partial agonists of the NMDA receptor to reduce opiate induced tolerance and dependence |
| US5605911A (en) | 1995-01-31 | 1997-02-25 | Washington University | Use of alpha-2 adrenergic drugs to prevent adverse effects of NMDA receptor hypofunction (NRH) |
| US6335358B1 (en) | 1995-04-12 | 2002-01-01 | President And Fellows Of Harvard College | Lactacystin analogs |
| US5741778A (en) | 1996-03-19 | 1998-04-21 | Amgen Inc. | Method for treating Huntington's disease using glial cell line-derived neurotrophic factor (GDNF) protein product |
| US5763393A (en) | 1996-05-17 | 1998-06-09 | Neurotherapeutics L.P. | Neuroactive peptides |
| PL330348A1 (en) | 1996-06-07 | 1999-05-10 | Zeneca Ltd | Peptidic derivatives |
| EP0918859A1 (en) | 1996-08-02 | 1999-06-02 | ZymoGenetics, Inc. | Testis-specific insulin homolog polypeptides |
| US5902815A (en) | 1996-09-03 | 1999-05-11 | Washington University | Use of 5HT-2A serotonin agonists to prevent adverse effects of NMDA receptor hypofunction |
| JP3955345B2 (ja) | 1996-09-27 | 2007-08-08 | サントリー株式会社 | 新規アミノ酸ダイジハーベイン |
| WO1999024584A1 (en) | 1997-11-12 | 1999-05-20 | Neurotherapeutics | Methods for the detection and treatment of disease using a glycosyltransferase |
| US5952389A (en) | 1998-01-13 | 1999-09-14 | Synchroneuron | Methods of treating tardive dyskinesia and other movement disorders |
| US6007841A (en) | 1998-03-13 | 1999-12-28 | Algos Pharmaceutical Corporation | Analgesic composition and method for treating pain |
| US6274314B1 (en) | 1998-04-02 | 2001-08-14 | Nyxis Neurotherapies, Inc. | Diagnostic assay for the modified nucleosides pseudouridine, 7-methyladenosine, or 1-methyladenosine |
| US6197820B1 (en) | 1998-04-06 | 2001-03-06 | Uab Research Foundation | Use of phenylglycine derivatives to decrease neuronal death caused by brain tumors and brain lesions |
| US6025471A (en) | 1998-06-03 | 2000-02-15 | Deghenghi; Romano | Diazaspiro, azepino and azabicyclo therapeutic peptides |
| US6194158B1 (en) | 1998-11-12 | 2001-02-27 | Nyxis Neurotherapies, Inc. | Diagnostic assay for cancer |
| US20030064921A1 (en) | 1999-10-27 | 2003-04-03 | The Regents Of The University Of California | Methods and compounds for modulating melanocortin receptor ligand binding and activity |
| AU1922301A (en) | 1999-11-17 | 2001-05-30 | Nyxis Neurotherapies, Inc. | Differential gene expression in cancer |
| WO2001057240A2 (en) | 2000-02-01 | 2001-08-09 | Agy Therapeutics, Inc. | Interaction of nmda receptor with protein tyrosine phosphatase |
| AU2001268467A1 (en) | 2000-06-14 | 2001-12-24 | Nyxis Neurotherapies, Inc. | Identification of genes and compounds for treatment of cancer |
| WO2001098367A2 (en) | 2000-06-22 | 2001-12-27 | Nyxis Neurotherapies, Inc. | Neuroactive peptides for treatment of hypoxia and related conditions |
| GB0018272D0 (en) | 2000-07-25 | 2000-09-13 | Vernalis Research Limited | Chemical compounds IV |
| EP1186303A3 (en) | 2000-09-06 | 2003-12-10 | Pfizer Products Inc. | Pharmaceutical combinations, for the treatment of stroke and traumatic brain injury, containing a neutrophil inhibiting factor and an selective NMDA-NR2B receptor antagonist |
| IL145209A0 (en) | 2000-09-06 | 2002-06-30 | Pfizer Prod Inc | Pharmaceutical combinations for the treatment of stroke and traumatic brain injury |
| UA73619C2 (en) | 2000-12-13 | 2005-08-15 | Pfizer Prod Inc | Stable pharmaceutical compositions of nmda receptor agonist (variants) and method of treatment |
| US20020142287A1 (en) | 2000-12-14 | 2002-10-03 | Hirotaka Yamamoto | High throughput assay to detect inhibitors of the map kinase pathway |
| US20030065138A1 (en) | 2001-03-07 | 2003-04-03 | University Of Utah Research Foundation | Linear gamma-carboxyglutamate rich conotoxins |
| AU2002255705A1 (en) | 2001-03-12 | 2002-09-24 | Nyxis Neurotherapies, Inc | Neuroactive peptides for prevention and/or treatment of hypoxia and neuropathic pain |
| WO2003010540A1 (en) | 2001-07-25 | 2003-02-06 | Nyxis Neurotherapies, Inc. | Method of identifying nmda-related agent |
| ATE451373T1 (de) | 2002-07-05 | 2009-12-15 | Targacept Inc | N-aryl diazaspirozyklische verbindungen, deren verwendung und das verfahren zu ihren herstellung |
| US7273889B2 (en) | 2002-09-25 | 2007-09-25 | Innovative Drug Delivery Systems, Inc. | NMDA receptor antagonist formulation with reduced neurotoxicity |
| EP1660634A4 (en) | 2003-08-08 | 2009-02-18 | Burnham Inst | P16-mediated regulation of NMDA receptors |
| WO2005020973A2 (en) | 2003-08-29 | 2005-03-10 | The University Of Houston System | Compositions having antimycrobial activity including a hydroxamate or a hydroxamate and a hydroxylamine |
| GB0323204D0 (en) | 2003-10-03 | 2003-11-05 | Novartis Ag | Organic compounds |
| US20050096311A1 (en) | 2003-10-30 | 2005-05-05 | Cns Response | Compositions and methods for treatment of nervous system disorders |
| WO2006034196A1 (en) | 2004-09-17 | 2006-03-30 | Lifelike Biomatic Inc. | Compositions for enhancing memory and methods therefor |
| EP2494976A1 (en) | 2005-03-24 | 2012-09-05 | Emory University | Methods for the treatment of a traumatic central nervous system injury |
| CA2617042A1 (en) * | 2005-07-29 | 2007-02-01 | Takeda Pharmaceutical Company Limited | Spiro-cyclic compound |
| WO2007025141A2 (en) | 2005-08-26 | 2007-03-01 | Wisconsin Alumni Research Foundation | Poly-beta-peptides from functionalized beta-lactam monomers and antibacterial compositions containing same |
| AR059224A1 (es) | 2006-01-31 | 2008-03-19 | Jerini Ag | Compuestos para la inhibicion de integrinas y uso de estas |
| US20070208001A1 (en) | 2006-03-03 | 2007-09-06 | Jincong Zhuo | Modulators of 11- beta hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same |
| WO2008033464A2 (en) | 2006-09-15 | 2008-03-20 | Schering Corporation | Azetidinone derivatives for the treatment of disorders of the lipid metabolism |
| JP2008188285A (ja) | 2007-02-06 | 2008-08-21 | Bridgestone Corp | バックパッド及び車両用シート |
| CN101066945B (zh) | 2007-05-25 | 2010-05-19 | 中国科学院上海有机化学研究所 | 一种合成3-位取代内酰胺类化合物的方法 |
| CN101125817B (zh) | 2007-08-03 | 2011-09-14 | 中国科学院上海有机化学研究所 | 一种合成高对映选择性醛基取代小环胺类化合物和光学活性3-位取代内酰胺类化合物的方法 |
| WO2009039390A2 (en) | 2007-09-20 | 2009-03-26 | Naurex Inc. | The development of glycobiology-based therapeutics for the treatment of brain tumors |
| WO2009105718A1 (en) | 2008-02-20 | 2009-08-27 | The Children's Hospital Of Philadelphia | Genetic alterations associated with autism and the autistic phenotype and methods of use thereof for the diagnosis and treatmemt of autism |
| CN102076679A (zh) | 2008-06-27 | 2011-05-25 | 神经研究公司 | 新颖的四甲基取代的哌啶衍生物及其作为单胺神经递质再摄取抑制剂的用途 |
| EP2323981B1 (en) | 2008-08-07 | 2014-03-12 | F. Hoffmann-La Roche AG | Process for the preparation of a macrocycle |
| GB0814991D0 (en) | 2008-08-15 | 2008-09-24 | Glaxo Group Ltd | Compounds |
| JP5702288B2 (ja) | 2008-09-18 | 2015-04-15 | ノースウエスタン ユニバーシティ | Ｎｍｄａレセプターモジュレータ及びその用途 |
| WO2010065709A2 (en) | 2008-12-03 | 2010-06-10 | Amin Khan | Hydroxamic acid derivatives, preparation and therapeutic uses thereof |
| DE102009001460B4 (de) | 2009-03-11 | 2010-12-02 | Zf Friedrichshafen Ag | Ölbehälter |
| WO2011003064A2 (en) | 2009-07-02 | 2011-01-06 | Naurex, Inc. | Methods of treating neuropathic pain |
| WO2011044089A2 (en) | 2009-10-05 | 2011-04-14 | Joseph Moskal | Methods of treating depression and other related diseases |
| US8951968B2 (en) | 2009-10-05 | 2015-02-10 | Northwestern University | Methods of treating depression and other related diseases |
| CA2789331C (en) | 2010-02-11 | 2017-11-07 | Northwestern University | Secondary structure stabilized nmda receptor modulators and uses thereof |
| KR101692275B1 (ko) | 2010-02-11 | 2017-01-04 | 노오쓰웨스턴 유니버시티 | ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도 |
| US8097634B2 (en) | 2010-04-15 | 2012-01-17 | Hoffmann-La Roche Inc. | Azacyclic derivatives |
| TW201245116A (en) | 2010-08-12 | 2012-11-16 | Tetraphase Pharmaceuticals Inc | Tetracycline analogs |
| US9737531B2 (en) | 2012-07-12 | 2017-08-22 | Glytech, Llc | Composition and method for treatment of depression and psychosis in humans |
| KR20210046843A (ko) | 2011-04-27 | 2021-04-28 | 노오쓰웨스턴 유니버시티 | 알츠하이머병, 헌팅톤병, 자폐증 또는 기타 장애의 치료 방법 |
| WO2013001448A1 (en) | 2011-06-27 | 2013-01-03 | Koninklijke Philips Electronics N.V. | Ultrasound transducer assembly and method of manufacturing the same |
| EP3009431B1 (en) | 2011-07-27 | 2017-10-25 | Astrazeneca AB | 2-(2,4,5-substituted-anilino)pyrimidine derivatives as egfr modulators useful for treating cancer |
| EP2951182B1 (en) | 2013-01-29 | 2020-03-18 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
| CN105308049A (zh) | 2013-01-29 | 2016-02-03 | 阿普廷伊克斯股份有限公司 | 螺-内酰胺nmda受体调节剂及其用途 |
| US9512134B2 (en) | 2013-01-29 | 2016-12-06 | Aptinyx, Inc. | Spiro-lactam NMDA receptor modulators and uses thereof |
| CA2898863A1 (en) | 2013-01-29 | 2014-08-07 | Naurex, Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
| WO2014120789A1 (en) | 2013-01-29 | 2014-08-07 | Naurex, Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
| AU2017267708B2 (en) | 2016-05-19 | 2020-02-20 | Aptinyx Inc. | Spiro-lactam NMDA receptor modulators and uses thereof |
| WO2017201285A1 (en) | 2016-05-19 | 2017-11-23 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
| CN109661398B (zh) | 2016-08-01 | 2022-07-05 | 阿普廷伊克斯股份有限公司 | 螺-内酰胺和二-螺-内酰胺nmda受体调节剂及其用途 |
| KR102465757B1 (ko) | 2016-08-01 | 2022-11-09 | 앱티닉스 인크. | 스피로-락탐 nmda 수용체 조정제 및 그의 용도 |
| EP3490974B1 (en) | 2016-08-01 | 2023-12-06 | Tenacia Biotechnology (Hong Kong) Co., Limited | Spiro-lactam nmda receptor modulators and uses thereof |
| AU2017306152A1 (en) | 2016-08-01 | 2019-01-31 | Aptinyx Inc. | Spiro-lactam NMDA receptor modulators and uses thereof |
| CN109843889B (zh) | 2016-08-01 | 2022-03-15 | 阿普廷伊克斯股份有限公司 | 螺-内酰胺nmda调节剂和使用其的方法 |
-
2017
- 2017-08-01 CN CN201780054216.8A patent/CN109661398B/zh active Active
- 2017-08-01 ES ES17751917T patent/ES2979128T3/es active Active
- 2017-08-01 WO PCT/US2017/044861 patent/WO2018026792A1/en active Application Filing
- 2017-08-01 EP EP17751917.0A patent/EP3490994B8/en active Active
- 2017-08-01 BR BR112019001926A patent/BR112019001926A2/pt not_active IP Right Cessation
- 2017-08-01 JP JP2019505250A patent/JP2019527235A/ja not_active Ceased
- 2017-08-01 US US16/321,906 patent/US11028095B2/en active Active
- 2017-08-01 MX MX2019001322A patent/MX2019001322A/es unknown
- 2017-08-01 SG SG11201900546UA patent/SG11201900546UA/en unknown
- 2017-08-01 AU AU2017306158A patent/AU2017306158B2/en not_active Ceased
- 2017-08-01 PE PE2019000295A patent/PE20190502A1/es unknown
- 2017-08-01 CA CA3031562A patent/CA3031562A1/en active Pending
- 2017-08-01 KR KR1020197005664A patent/KR102462288B1/ko active IP Right Grant
- 2017-08-01 EA EA201990425A patent/EA201990425A1/ru unknown
- 2017-08-01 IL IL264496A patent/IL264496B/en unknown
-
2019
- 2019-01-30 CL CL2019000249A patent/CL2019000249A1/es unknown
- 2019-01-30 CO CONC2019/0000944A patent/CO2019000944A2/es unknown
-
2021
- 2021-05-07 US US17/314,174 patent/US20220098211A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN109661398A (zh) | 2019-04-19 |
| CO2019000944A2 (es) | 2019-02-08 |
| PE20190502A1 (es) | 2019-04-10 |
| KR102462288B1 (ko) | 2022-11-01 |
| BR112019001926A2 (pt) | 2019-08-06 |
| EP3490994C0 (en) | 2024-02-07 |
| US20220098211A1 (en) | 2022-03-31 |
| US20200181159A1 (en) | 2020-06-11 |
| ES2979128T3 (es) | 2024-09-24 |
| IL264496B (en) | 2022-09-01 |
| CA3031562A1 (en) | 2018-02-08 |
| IL264496A (ko) | 2019-03-31 |
| JP2019527235A (ja) | 2019-09-26 |
| CL2019000249A1 (es) | 2019-06-21 |
| WO2018026792A1 (en) | 2018-02-08 |
| CN109661398B (zh) | 2022-07-05 |
| EA201990425A1 (ru) | 2019-08-30 |
| KR20190037276A (ko) | 2019-04-05 |
| EP3490994B8 (en) | 2024-03-13 |
| AU2017306158A1 (en) | 2019-01-31 |
| EP3490994B1 (en) | 2024-02-07 |
| MX2019001322A (es) | 2019-09-11 |
| US11028095B2 (en) | 2021-06-08 |
| EP3490994A1 (en) | 2019-06-05 |
| AU2017306158B2 (en) | 2021-10-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201900554YA (en) | Spiro-lactam nmda modulators and methods of using same | |
| SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900443VA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201909949XA (en) | Targeted immunotolerance | |
| SG11201908330PA (en) | Farnesoid x receptor agonists and uses thereof | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201807784SA (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
| SG11201906883SA (en) | Methods for the administration of certain vmat2 inhibitors | |
| SG11201811564QA (en) | Methods of treating ovarian cancer | |
| SG11201908786VA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201808237UA (en) | Substituted indole compound derivatives as dengue viral replication inhibitors | |
| SG11201808138YA (en) | Substituted indole derivatives as dengue viral replication inhibitors | |
| SG11201811442UA (en) | Formulation of a peptide vaccine | |
| SG11201908465QA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201808270PA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201811230RA (en) | Compositions and methods for reducing ocular neovascularization | |
| SG11201809751XA (en) | Egfr inhibitor compounds | |
| SG11201907804QA (en) | Pharmaceutical composition comprising selexipag | |
| SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
| SG11201809908TA (en) | Stabilized glycopeptide antibiotic formulations | |
| SG11201900238UA (en) | Compounds and methods for modulation of smn2 |